Inhibition of EZH2 exerts antitumorigenic effects in renal cell carcinoma via LATS1open access
- Authors
- Hong, Seong Hwi; Hwang, Hyun Ji; Son, Da Hyeon; Kim, Eun Song; Park, Sung Yul; Yoon, Young Eun
- Issue Date
- Apr-2023
- Publisher
- WILEY
- Keywords
- EZH2; Hippo pathway; LATS1; renal cell carcinoma; tazemetostat
- Citation
- FEBS OPEN BIO, v.13, no.4, pp.724 - 735
- Indexed
- SCIE
SCOPUS
- Journal Title
- FEBS OPEN BIO
- Volume
- 13
- Number
- 4
- Start Page
- 724
- End Page
- 735
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/191622
- DOI
- 10.1002/2211-5463.13579
- ISSN
- 2211-5463
- Abstract
- The most common type of kidney cancer in adults is renal cell carcinoma (RCC), which accounts for approximately 90% of cases. RCC is a variant disease with numerous subtypes; the most common subtype is clear cell RCC (ccRCC, 75%), followed by papillary RCC (pRCC, 10%) and chromophobe RCC (chRCC, 5%). To identify a genetic target for all subtypes, we analyzed The Cancer Genome Atlas (TCGA) databases of ccRCC, pRCC, and chromophobe RCC. Enhancer of zeste homolog 2 (EZH2), which encodes a methyltransferase, was observed to be significantly upregulated in tumors. The EZH2 inhibitor tazemetostat induced anticancer effects in RCC cells. TCGA analysis revealed that large tumor suppressor kinase 1 (LATS1), a key tumor suppressor of the Hippo pathway, was significantly downregulated in tumors; the expression of LATS1 was increased by tazemetostat. Through additional experiments, we confirmed that LATS1 plays a crucial role in EZH2 inhibition and has a negative association with EZH2. Therefore, we suggest that epigenetic control could be a novel therapeutic strategy for three subtypes of RCC.
- Files in This Item
-
- Appears in
Collections - 서울 의과대학 > 서울 비뇨의학교실 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/191622)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.